Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax` Global Production Capacity to Over 2 Billion Doses Annually
(WorldNews Denmark)

Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021 Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in 2021 Agreement expands Novavax partnership with world`s largest vaccine developer to increase global delivery of NVX-CoV2373 GAITHERSBURG, Md., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXâ€`CoV2373,...